Agennix AG, Planegg/Martinsried

Address

Company description and purpose of company Agennix AG

Agennix is ​​a biopharmaceutical company that was formed in November 2009 through the merger of GPC Biotech AG and Agennix, Inc. Agennix is ​​developing new therapeutics for indications with significant unmet medical need that have the potential to achieve significant improvements in the life span and quality of critically ill patients. The company's most advanced active ingredient is talactoferrin, an orally administered therapy that has been shown to be effective in randomized, double-blind, placebo-controlled phase 2 studies in non-small cell lung cancer and in severe blood poisoning (sepsis). Talactoferrin is currently in Phase 3 clinical development in non-small cell lung cancer and the Company intends to advance the program for the treatment of severe sepsis. The company's other clinical development programs include: RGB-286638, a kinase inhibitor targeting a variety of protein kinases (in phase 1 development), the orally available platinum-based active ingredient satraplatin, and a topical form (as a gel) of talactoferrin for treatment of diabetic foot ulcers. Agennix's registered office is in Heidelberg. The company has three operational locations: Martinsried / Munich; Princeton, New Jersey and Houston, Texas.

Translated by google.com

The company Agennix AG on Fraunhoferstraße 20 in 82152 Planegg/Martinsried is listed on Yellowpages.swiss. Latitude and longitude coordinates for Agennix AG are: 48.11135 and 11.44992. The unique identification number of this portrait is YPW-249973.

The company Agennix AG is listed in the branch Medicine - Hospital - Doctor. The company Agennix AG offers its services in the following categories: Hospital equipment, Medicines, pharmacy companies, other products or services according to the company's purpose.

---

Data Source: HELP.CH your e-guide ®